Evaluating the use of the heart age tool in community pharmacies: a 4-week cluster-randomized controlled trial.

Karianne Svendsen, David R Jacobs, Lisa T Mørch-Reiersen, Kjersti W Garstad, Hege Berg Henriksen, Vibeke H Telle-Hansen, Kjetil Retterstøl

Journal: European journal of public health 2021;30(6):1139-1145

PMID: 32206810

Abstract

BACKGROUND

Joint British Societies have developed a tool that utilizes information on cardiovascular disease (CVD) risk factors to estimate an individual's 'heart age'. We studied if using heart age as an add-on to conventional risk communication could enhance the motivation for adapting to a healthier lifestyle resulting in improved whole-blood cholesterol and omega-3 status after 4 weeks.

METHODS

A total of 48 community pharmacies were cluster-randomized to use heart age+conventional risk communication (intervention) or only conventional risk communication (control) in 378 subjects after CVD risk-factor assessment. Dried blood spots were obtained with a 4-week interval to assay whole-blood cholesterol and omega-3 fatty acids. We also explored pharmacy-staff's (n=27) perceived utility of the heart age tool.

RESULTS

Subjects in the intervention pharmacies (n=137) had mean heart age 64 years and chorological age 60 years. In these, cholesterol decreased by median (interquartile range) -0.10 (-0.40, 0.35) mmol/l. Cholesterol decreased by -0.20 (-0.70, 0.30) mmol/l (P difference =0.24) in subjects in the control pharmacies (n=120) with mean chronological age 60 years. We observed increased concentrations of omega-3 fatty acids after 4 weeks, non-differentially between groups. Pharmacy-staff (n=27) agreed that heart age was a good way to communicate CVD risk, and most (n=25) agreed that it appeared to motivate individuals to reduce elevated CVD risk factors.

CONCLUSIONS

The heart age tool was considered a convenient and motivating communication tool by pharmacy-staff. Nevertheless, communicating CVD risk as heart age was not more effective than conventional risk communication alone in reducing whole-blood cholesterol levels and improving omega-3 status.

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved.

Address: Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.; The Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway.; Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.; Boots Norge AS, Oslo, Norway.; Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.